CSPC Pharmaceutical’s Sirolimus Injection Gains Breakthrough Therapy Status in China

An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.

CSPC Pharmaceutical Group announced that its Sirolimus for Injection (albumin-bound) has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for treating malignant perivascular epithelioid cell tumor (PEComa). This designation is expected to expedite the development of the drug, potentially making it the first standard treatment for PEComa in China. The product is also undergoing clinical trials for various cancers, including breast cancer, where it addresses significant unmet needs, particularly for patients resistant to current treatments.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. The company focuses on developing innovative drugs and therapies, with a market focus on addressing unmet clinical needs in China.

YTD Price Performance: 8.47%

Average Trading Volume: 3,997

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $7.39B

For an in-depth examination of 1093 stock, go to TipRanks’ Stock Analysis page.